End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes end‐stage kidney disease at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in total remission at final compared with alkylating agents ± steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in complete remission at final compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in recurrence of disease (relapse) at final compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes 100% increase in SCr at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ infection ( · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in adverse events ‐ infection ( compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
Malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Hospital mortality – non‐randomised studies ( · adult on acute hospital wards at risk of clinical deterioration
2 findings from 1 review
AOR 0.52 [0.32, 0.85]
2792 participants
Low
no estimate extracted
Studies not reported
Very low
Length of hospital stay · adult on acute hospital wards at risk of clinical deterioration
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
HR 0.91 [0.83, 0.98]
2733 participants
Low
Adverse events (unexpected cardiac or respiratory arrest) – non‐randomised studies ( · adult on acute hospital wards at risk of clinical deterioration
2 findings from 1 review
AOR 0.94 [0.79, 1.13]
364094 participants
Low
no estimate extracted
Studies not reported
Very low
Composite outcome – non‐randomised studies Composite endpoint of cardiopulmonary arrest, unplanned ICU admission or death per 1000 admitted patients ( · adult on acute hospital wards at risk of clinical deterioration
1 finding from 1 review
AOR 0.85 [0.72, 0.99]
57858 participants
Low
Unplanned ICU admission – non‐randomised trial ( · adult on acute hospital wards at risk of clinical deterioration
2 findings from 1 review
AOR 1.04 [0.89, 1.21]
364094 participants
Low
no estimate extracted
Studies not reported
Very low
ICU readmission – non‐randomised studies · adult on acute hospital wards at risk of clinical deterioration
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Change in weight (kg) · People wanting to quit smoking
Behavioural weight management interventions showed no clear difference in mean weight change (kg) at end of treatment ‐ Weight management… compared with brief advice or no intervention (low certainty).
6 findings from 1 review
MD 0.04
2 studies · 140 participants
Low
MD 0.89
2 studies · 81 participants
Low
MD 0.21
2 studies · 61 participants
Very low
Show 3 more findings
MD 1.11
3 studies · 121 participants
Low
MD 0.96
5 studies · 816 participants
Very low
MD 0.44
4 studies · 530 participants
Very low
Cessation · People wanting to quit smoking
Behavioural weight management interventions may leads to lower smoking cessation at 12 months ‐ Personalised weight management… compared with brief advice or no intervention (low certainty).
2 findings from 1 review
Change in weight (kg) · People wanting to quit smoking
3 findings from 1 review
no estimate extracted
3 studies · 169 participants
Very low
MD 0
3 studies · 106 participants
Low
MD 0.7
2 studies · 76 participants
Very low
Smoking cessation · People wanting to quit smoking
Acceptance interventions for weight concern may leads to higher smoking cessation at 6 months compared with no weight management intervention (low certainty).
1 finding from 1 review
Behaviour change: smoking cessation · People wanting to quit smoking
Acceptance interventions for weight concern showed no clear difference in smoking cessation at 12 months compared with no weight management intervention (low certainty).
1 finding from 1 review
Change in weight (kg) · People who have quit smoking
Exercise interventions for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with no exercise intervention (low certainty).
2 findings from 1 review